Paper Review — Verify Claims Fast

Context and objective

Bleeding disorder of unknown cause BDUC is a diagnosis of exclusion in patients with a clinically relevant bleeding tendency but normal routine coagulation and platelet testing. Mehic and colleagues asked whether plasmin generation kinetics and clot architecture differ in patients with BDUC and whether PG plus fibrinogen can help discriminate BDUC from healthy controls.

Primary study description and main headline result: In a case-control analysis of 375 BDUC patients and 100 age matched healthy controls, calibrated fluorogenic plasmin generation (PG) showed longer lag and TTP times, lower velocity and lower peak plasmin but higher endogenous plasmin potential (EPP) in BDUC; peak plasmin correlated positively with maximum plasma clot absorbance and inversely with fibrin fiber diameter; a multivariable model combining fibrinogen with PG parameters discriminated BDUC from healthy controls (AUC approx 0.85) Mehic et al. 2024 Blood Advances Paper

Key methods (what was actually measured)

• PG assay in citrated platelet poor plasma using exogenous tissue factor and addition of exogenous tPA (0.62 μg/mL) with calibrated fluorogenic substrate readout (Thrombinoscope software) to extract lag time, time to peak TTP, velocity, peak plasmin, and endogenous plasmin potential EPP PG assay methods
• Turbidimetric plasma clot formation and lysis (OD405nm) with exogenous tPA for clot lysis time (CLT) and maximum absorbance (clot density) in a subset (293/375 BDUC had turbidimetry) Turbidity assay description
• Confocal microscopy of fibrin network (AlexaFluor488 fibrinogen) for fiber diameter and density in a small random subsample (BDUC n=6, HC n=9) with manual ImageJ measurements Confocal microscopy methods
• ELISAs for fibrinolytic factors (tPA, active PAI-1, alpha2-antiplasmin, TAFI), FXIII activity and D-dimer Fibrinolytic factor assays

Key quantitative results (data extracted)

Interpretation and mechanistic plausibility

The central paradox in the paper is that patients with clinical bleeding (BDUC) show reduced peak plasmin generation rather than the hyperfibrinolytic profile one might expect. The authors propose a model in which altered clot architecture (thicker, coarser fibrin fibers and higher turbidity) reduces plasmin formation on the fibrin surface (fewer accessible C-terminal lysines), thereby lowering measured peak plasmin while clots remain more susceptible to fibrinolysis in bulk assays because coarse fibers can be lysed faster once plasmin is formed—so PG and lysis assays capture different dynamics Proposed mechanistic explanation

This is biologically plausible because plasminogen activation is fibrin-dependent and relies on lysine binding sites and fibrin architecture; factors such as TAFI and alpha2-antiplasmin change fibrin surface properties and plasmin inhibition kinetics. However, in this cohort measured TAFI and alpha2AP did not correlate with peak plasmin, weakening a straightforward inhibitor-based explanation for the decreased PG signal in BDUC TAFI alpha2AP caveat

Strengths

• Large well characterized BDUC cohort (n=375) with matched healthy controls and multiple orthogonal assays (PG, turbidity, confocal imaging, fibrinolytic factors) Study strengths
• Appropriate statistical modeling with cross-validation and sensitivity analyses for ST time handling

Limitations and potential biases

• PG assay used exogenous tPA and TF and the calibrated Thrombinoscope pipeline does not capture endogenous active tPA or PAI-1 activity; this limits physiological inference about in vivo fibrinolytic balance PG assay limitation
• Large number of samples required manual ST time imputation (BDUC 184, HC 81) because software errors prevented automatic calculation; manual setting introduces possible bias despite blinded procedure and sensitivity checks
• Confocal fibrin architecture data derive from a very small subsample (6 BDUC, 9 HC) limiting confidence in generalization of fiber diameter findings (r = -0.561 P = 0.03 is hypothesis generating) Small confocal N
• Single center Vienna cohort may limit external validity; demographics showed female predominance and blood group O overrepresentation typical for VIBB cohorts but may not match other populations
• No correction for multiple testing was performed (authors state exploratory/hypothesis generating), increasing false positive risk for secondary correlations
• Data availability: raw data not deposited publicly in the manuscript, hindering reproducibility and external validation

Practical and clinical implications

1. PG profiling adds information complementary to clot lysis and turbidity assays and may identify a subgroup of BDUC patients with altered clot architecture and reduced PG capacity; however, the direction of causality is not proven by this cross-sectional design Clinical implications from paper
2. Model discrimination (AUC~0.85) is promising for diagnostic stratification but needs independent validation in external cohorts before any clinical use
3. The lack of association between PG parameters and bleeding severity in this cohort argues that PG alone is not yet a severity biomarker for BDUC (no correlation with Vicenza or ISTH BAT scores) PG and bleeding severity

How to improve and next experiments

• External validation: apply the same PG assay, turbidimetry and confocal imaging pipeline to an independent BDUC cohort (different center, different population) to test generalizability and validate the AUCs.
• Mechanistic tests: perform PG assays with and without exogenous tPA, and measure active endogenous tPA and PAI-1 activity in parallel; use surface-bound fibrin models to measure plasminogen binding kinetics and plasmin formation rates directly on fibrin of defined architecture.
• Scale up confocal/fiber analysis: systematically measure fiber diameter and density in a much larger, stratified sample (for example 50 BDUC vs 50 HC) and use automated image analysis to avoid bias from manual measurement.
• Functional rescue experiments: explore whether modifying fibrin architecture in vitro (alter thrombin or fibrinogen concentration, add FXIII) alters PG readouts in BDUC vs HC plasma, to test causality.
• Make raw data public (PG curves, turbidimetry, confocal images) so other groups can reproduce parameter extraction and modeling.

Bottom line and confidence

Mehic et al. provide robust, carefully measured evidence that plasmin generation kinetics are altered in a large BDUC cohort and that these alterations associate with clot structural metrics; their model discriminates BDUC from controls with good AUC but mechanistic causality remains unproven and small-sample imaging results require replication Paper conclusion

Interactive plots and further analysis

I can (1) reconstruct summary plots of PG parameters (median values with IQR), (2) reproduce the ROC curve for their final model using the reported AUCs, and (3) make a scatter plot of peak plasmin versus maximum absorbance and fiber diameter using the extracted r values and sample sizes as estimates. If you want me to run full numerical reanalysis on raw curves or produce reproducible figures from raw data you will need to supply the raw PG and turbidimetry/ confocal datasets or allow me to run a BGPT biology agent to fetch/process them.

Key source

Mehic et al. 2024 Blood Advances Paper

Author review links